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ess: heikki.koskela@kuhSummary There is significant overlap in the responsiveness to direct airway
challenges, such as the histamine challenge, between asthmatic and non-asthmatic
subjects, which decreases their accuracy in the diagnosis of asthma. To minimise this
overlap, a new test, hypertonic histamine challenge, was developed. Fifteen healthy
subjects, 16 subjects with steroid-naive asthma, and 16 asthmatic subjects
undergoing inhaled corticosteroid treatment underwent inhalation challenges with
hypertonic saline, isotonic histamine, and hypertonic histamine, using an ultrasonic
nebuliser and 2-min tidal breathing method. The increase in histamine solution
tonicity decreased the histamine PC20 values only in the steroid-naive asthmatic
subjects (1.1 (0.5–2.7) vs. 0.5 (0.2–1.2)mg/ml, P ¼ 0:047). Using 1mg/ml as the
cut-off value, the sensitivity, specificity, and accuracy of the hypertonic histamine
challenge to detect steroid-naive asthma was 81%, 100%, and 90%. The respective
values for the isotonic histamine challenge were 56%, 100%, and 77%. Furthermore,
there was a statistically significant difference in the hypertonic histamine PC20
between steroid-naive and steroid-treated asthmatic subjects, which could not be
detected in the isotonic histamine PC20. The hypertonic histamine PC20 was highly
repeatable, with a single determination 95% range of 71.35 doubling concentra-
tions. The hypertonic histamine challenge was safe but provoked more cough and
throat irritation than the other two challenges. In conclusion, compared with a
conventional, isotonic histamine challenge, hypertonic histamine challenge may be
more accurate in the diagnosis of asthma and also, more capable to detect the
effects of inhaled corticosteroid treatment.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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It is widely accepted that physicians need objective
measurements to diagnose asthma,1,2 with tests to
measure airway hyperresponsiveness (AHR) being
among the most useful.1,3,4
Most investigators assess AHR using histamine or
methacholine as the provocative stimulus. These
stimuli evoke airflow limitation predominantly via a
direct effect on airway smooth muscle and the
response is usually expressed as either the provo-
cative concentration (PC20) or dose (PD20) produ-
cing a 20% fall in forced expiratory volume in 1 s
(FEV1).
5 Airway responsiveness to histamine or
methacholine is unimodally log-normally distribu-
ted within the population.5 This continuous dis-
tribution plus the 95% confidence interval (CI) of
repeatability in the range of 71.0–2.4 doubling
concentrations6–8 leads to a significant overlap in
responses between asthmatic and non-asthmatic
subjects, which decreases the accuracy of these
challenges in the diagnosis of asthma. In the
present study we describe a method to minimise
this overlap, in order to increase the diagnostic
accuracy of histamine challenge.
Indirect airway challenges, including hypertonic
saline challenge, induce airflow limitation by acting
on cells other than smooth muscle cells. They cause
the airways to narrow indirectly by provoking a
release of endogenous mediators from inflamma-
tory cells, epithelial cells, and nerves. They are
considered as less sensitive than the direct chal-
lenges in differentiating asthmatic subjects from
normal subjects, but their strength is in their high
specificity.5 Indeed, usually only asthmatic subjects
develop airflow limitation in response to inhaled
hypertonic saline whereas the changes in airflow
parameters in healthy subjects are negligible.9
Therefore, we hypothesised that if the histamine
challenge solution would be made hypertonic by
adding saline in it, the bronchoconstriction in
asthmatic subjects might appear at lower inhaled
histamine concentrations than during a conven-
tional isotonic histamine challenge. We also hy-
pothesised that the increase in the histamine
challenge solution tonicity would not alter the
histamine responsiveness in healthy subjects. As a
consequence, the difference in histamine respon-
siveness between asthmatic and healthy subjects
would thus increase. The present study was planned
to test these hypotheses. Since the asthmatic
subjects’ response to hypertonic aerosols can often
disappear after treatment with inhaled corticoster-
oids,10–13 we included an equal number of asth-
matic subjects with and without this treatment in
the present study, in addition to healthy controls.Materials and methods
Subjects
Forty-nine subjects were recruited for the study.
The asthmatic subjects were recruited from the
outpatient clinic of the authors’ hospital. All
asthmatic subjects were originally referred to the
authors’ hospital due to diagnostic uncertainty at
the primary health care level. They were included
if their symptoms suggested asthma14 and if they
showed variable airway obstruction in ambulatory
peak flow (PEF) monitoring, according to previously
described criteria.15 The diagnosis of asthma was
not based on any kind of bronchial provocation test
to avoid selection of subjects. The exclusion
criteria were a respiratory tract infection within
four weeks, and FEV1 less than 65% of predicted.
16
The patients in whom the staff physician consid-
ered COPD as the most probable diagnosis were
excluded, even if the variable airway obstruction
criteria in the ambulatory PEF monitoring were
fulfilled. There were 17 newly diagnosed asthmatic
subjects who had never used any corticosteroid
preparations and 17 asthmatic subjects who used
inhaled corticosteroids. However, one steroid-naive
subject discontinued the study due to an acute
respiratory tract infection and one steroid-treated
subject due to severe coughing and headache
during the hypertonic histamine challenge. The
steroid-naive asthmatic subjects had to be cur-
rently symptomatic, i.e., suffering of asthmatic
symptoms at least once per week. The 15 healthy
volunteers had no chronic respiratory diseases or
symptoms and were life-long non-smokers. Table 1
shows the basic characteristics of the 47 subjects
who completed the study. The seven current
smokers among the asthmatic subjects had smoked
median 5.5 (range 0.2–18) pack years. The Finnish
National Agency of Medicines and the Institutional
Ethics Committee approved this study and all
subjects provided their informed written consent
for participation in the study.Protocol
Skin prick tests were performed against common
aeroallergens (Soluprick SQs, ALK-Abello´, Ho¨r-
sholm, Denmark) and atopy was defined as at least
a 3mm wheal reaction to any of the allergens.17
The asthmatic subjects completed a symptom
questionnaire and their asthma severity was de-
termined using the Global Initiative for Asthma
classification.18 All subjects underwent three air-
way challenges in a random order, with at least two
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Table 1 The basic clinical characteristics of the subjects.
Healthy subjects,
n ¼ 15
Steroid-naive asthmatic
subjects, n ¼ 16
Asthmatic subjects with
steroid treatment,
n ¼ 16
Age (years) 33 (20–56) 41 (20–61) 44 (23–74)
Gender distribution (F ¼ females,
M ¼ males)
9 F, 6 M 11 F, 5 M 10 F, 6 M
Number of atopic subjects 5 8 4
Number of current smokers 0 5 2
GINA classification of asthma
severity
Mild persistent 4
moderate persistent 12
Intermittent 6 mild
persistent 2 moderate
persistent 8
FEV1 (% of predicted
y) 101 (87–130) 92 (70–109) 90 (66–115)
Duration of asthmatic symptoms
(months)z
24 (6–408) 30 (12–240)
Duration of the inhaled
corticosteroid treatment (months)z
7 (3–60)
Daily inhaled corticosteroid dose
(ug)y
797 (400–1600)
The data is expressed as means, with the minimum and the maximum values in parenthesis.
Global Initiative for Asthma.18
yThe reference values are those of Viljanen et al.16
zExpressed as the median value, with the minimum and the maximum in parenthesis.
yThe amounts indicate directly the dose of beclomethasone and budesonide. The fluticasone dose is multiplied by two.
H.O. Koskela et al.728nights between the challenges, approximately at
the same time of the day, within 3 weeks. The
challenge solutions were hypertonic saline, isotonic
histamine and hypertonic histamine. The asthmatic
subjects also underwent a second hypertonic
histamine challenge, to study its repeatability.
For safety reasons, all healthy subjects were
studied first, between April and August, followed
by the asthmatic subjects between September and
April, i.e., outside the pollen season. The study was
not blinded.The challenges
Subjects had refrained from taking aerosol short-
acting beta2 agonists for 6 h, aerosol long-acting
beta2 agonists for 48 h, and antihistamine and
leucotriene receptor antagonists for 3 days before
the challenges. Inhaled corticosteroids were not
taken on the study days.
First, current symptoms were assessed using
120mm visual analogy scale lines, one line for
each of the following symptoms: Headache, skin
flushing, nausea, throat irritation, and dyspnoea.
Blood pressure (Omron 711, Omron Ltd., Tokyo,
Japan) and heart rate were measured. After that
spirometry (Model M9449, Medikro Ltd, Kuopio,
Finland) and PEF measurements (The Mini Wright,Clement Clarke International Ltd., Harlow, UK)
were carried out at least three times, but not more
than eight times, according to the American
Thoracic Society guidelines19 and the largest FEV1
and PEF values were used as baseline values.
Every challenge was performed in a similar way,
only the challenge solutions changed. Each solution
was inhaled for 2min using tidal volume breathing.
Spirometry was performed in duplicate at 90 s from
the end of the inhalation and the larger of the two
FEV1 values was used for analysis. The inhalation of
the next solution began 4min after the start of the
previous inhalation and the challenge continued
until the FEV1 had fallen 20% or more from the
baseline, or up to the inhalation of the final
solution.
The airway responsiveness to isotonic and hyper-
tonic histamine challenges was expressed as PC20
by linear interpolation of the relationship between
the percent decrease in FEV1 and the concentration
of histamine solution required to provoke the
decrease. If the fall in FEV1 was smaller than 20%
after the final histamine concentration, an arbi-
trary value of 16mg/ml (twice the maximal
concentration administered) was used as the PC20.
Coughs were manually recorded throughout the
challenges.
Immediately after the challenge, the symptoms
were assessed again, and the blood pressure and
ARTICLE IN PRESS
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decreased by 20% or more, the subject inhaled
0.2mg of salbutamol (Buventol Easyhaler, Orion
Ltd., Espoo, Finland) and the spirometry was
performed in duplicate at 15min thereafter. After
the latter of the two hypertonic histamine chal-
lenges, 10 asthmatic subjects did not inhale
salbutamol but their FEV1 values were monitored
in duplicate every 10min after the challenge up to
1 h, to follow their spontaneous recovery. After
all the challenges the subjects were asked to
record their PEF values in triplicate every second
hour until bedtime, and also on the next morning.
They were also encouraged to write down in a
symptom diary up to the next morning every
possible symptom which might be related to the
challenges.The nebuliser
A hand-held ultrasonic nebuliser was used (Omrons
U1, Omron Ltd., Tokyo, Japan). Before starting the
study the volume output of the nebuliser was
measured by nebulizing various solutions for 2min
with the mouthpiece attached and weighting
the nebuliser plus the mouthpiece before and
after nebulisation by a calibrated, high-quality
weighing machine, as previously described.20 The
output was steadily 0.44–0.48ml/min irrespective
whether the solution was water, isotonic saline,
hypertonic saline, isotonic histamine, or hypertonic
histamine within a concentration range of
0.0075–16mg/ml. The authors did not measure
the droplet size distribution of the nebuliser with
the various solutions. According to the manufac-
turer the mass median diameter of the nebuliser
is 6 mm. The same nebuliser was used throughout
the study.Table 2 Preparation of the hypertonic histamine challen
Matter Weight (g)
Hypertonic phosphate-buffered saline (HPBS)
NaH2PO4 1.808 ¼ N
Na2HPO4 7.576 ¼ N
NaCl 45.000
H2O (pH 7.40) ad 1
Hypertonic histamine diphosphate 8mg/ml (26mmol/l) s
Histamine diphosphate 8 ¼ H
HPBS ad 1
Other dilutions
Made by diluting the hypertonic histamine diphosphate 8The challenge solutions
The histamine solutions were prepared and pack-
aged by the Pharmacy Department of Kuopio
University Hospital. Briefly, the histamine dipho-
sphate powder (Histamini phosphas, Ph.Eur., Uni-
versity Pharmacy, Helsinki, Finland) was dissolved
in phosphate-buffered saline (PBS) solution or
hypertonic phosphate-buffered saline (HPBS) solu-
tion 8mg/ml. The PBS was prepared according to
an international recommendation21 and its osmol-
ality was 292mOsm/kg (measured by freezing-
point depression, using The AdvancedTM Micro
Osmometer 3300-BR, Advanced Instruments, Inc.,
Norwood, MA, USA). The formula for the prepara-
tion of HPBS is expressed in Table 2 and differs from
the PBS formula in that 45 g of NaCl was added
instead of 4.4 g, to achieve a high osmolality
(1511mOsm/kg). Other inhalation solutions were
made by diluting the isotonic or hypertonic
histamine diphosphate 8mg/ml solution with PBS
or HPBS, respectively. The solutions were sterilised
by filtration using a 0.22 mm polymer filter (Millex-
GV 0.22 mm, Millipore corp., Bedford, MA, USA).
Procedures were completed using aseptic techni-
ques under a laminar flow hood. The final product
was a unit-dose syringe containing 3ml of one of
the following concentrations of isotonic or hyper-
tonic histamine diphosphate solution: 0.0075,
0.015, 0.03, 0.06, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0,
and 8.0mg/ml. The osmolality of the isotonic
histamine dilutions was 291–341mOsm/kg and
that of the hypertonic histamine dilutions
1522–1577mOsm/kg. The syringes were stored in
dark location at 4 1C. Before the challenges, they
were allowed to equilibrate to room temperature
for 30min and were shaken well.
In the isotonic histamine challenge, the first
nebulised solution was pure PBS and in thege solutions.
Equivalent weight (g)
aH2PO4 2H2O 2.35
a2HPO4 12H2O 19.11
000ml
olution
DP 1H2O 8.48
000ml
mg/ml (26mmol/l) solution with HPBS
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The subsequent solutions were the isotonic or
hypertonic histamine diphosphate dilutions at
doubling concentrations, respectively. In the hy-
pertonic saline challenge the subjects inhaled the
HPBS all the time, up to twelve 2min inhalations.
The lung function measurements and the intervals
between the inhalations were identical to the
histamine challenges.Statistical analysis
The results are expressed as means and 95% CIs.
Due to the significant deviation of the distribution
from a normal distribution (one-sample Kolmogor-
ov–Smirnov test), the PC20 values are expressed as
geometric means and 95% CIs. Wilcoxon signed-rank
test was used for paired comparisons, Kruskal–Wal-
lis ANOVA was used to compare the results between
the three subgroups, with a post-hoc Mann–Whit-
ney test with Bonferroni correction to compare the
results between two subgroups. Spearman’s rho (rs)
was used to analyse correlations. To compare the
diagnostic accuracy of the histamine and hyper-
tonic histamine challenge as well as to detect the
best cut-off value in separating the steroid-naive
asthmatic patients and healthy subjects, receiver
operator characteristic (ROC) curves were graphi-
cally constructed by plotting sensitivity against
false-positive rate (1specificity) for several cut-
off values of PC20. Repeatability of the responsesTable 3 Airway responsiveness to the challenges.
Group Hypertonic saline
(% fall in FEV1
)
1: Healthy subjects 0.3 (2.8 to 2.2)
n ¼ 15
2: Steroid-naive asthmatic subjects 5.7 (9.7 to 1.7
n ¼ 16
3: Steroid-treated asthmatic
subjects
2.4 (6.4 to 1.6)
n ¼ 16
P valuez between the three groups 0.039
Paired comparisons between the
groups, P-valuesy
1 vs. 2: 0.040
1 vs. 3: 0.73
2 vs. 3: 0.13
Since the great majority of the subjects did not show a 20% fal
is expressed as the maximal percentage fall in FEV1.
yComparison between histamine and hypertonic histamine, Wil
zKruskal–Wallis ANOVA.
yMann–Whitney test with Bonferroni correction.was determined by using the single determination
95% range and the intraclass correlation coeffi-
cient.22 All analyses were carried out using SPSS for
Windows 9.0.Results
Airway responsiveness to the challenges
The increase in histamine challenge solution
tonicity significantly decreased the histamine PC20
values in the steroid-naive asthmatic subjects but
was without effect on those values in the healthy
subjects and in the steroid-treated asthmatic
subjects (Table 3). As a consequence, the hyper-
tonic histamine challenge differentiated the ster-
oid-naive asthmatic subjects from the healthy
subjects better than the isotonic histamine chal-
lenge, which could be demonstrated by the left-
upward shift of the ROC curve (Fig. 1). The ROC
curve suggested 1mg/ml as the best cut-off value
for both hypertonic and isotonic histamine PC20.
Using this cut-off value, the sensitivity, specificity
and diagnostic accuracy (steroid-naive asthmatics
with a positive test result plus healthy subjects
with a negative test result divided by the sum of
the two groups) of the hypertonic histamine
challenge were 81%, 100%, and 90%. The respective
values for the isotonic histamine challenge were
56%, 100%, and 77% (Fig. 2a and b). Also, there wasIsotonic
histamine
Hypertonic
histamine
P valuey
(PC20, mg/ml) (PC20, mg/ml)
7.8 (4.8–12.8) 8.2 (5.2–13.3) 0.95
) 1.1 (0.5–2.7) 0.5 (0.2–1.2) 0.047
2.0 (0.8–4.9) 2.3 (1.0–5.7) 0.98
0.003 o 0.0001
1 vs. 2: 0.004 1 vs. 2: o0.0001
1 vs. 3: 0.024 1 vs. 3: 0.050
2 vs. 3: 0.42 2 vs. 3: 0.016
l in FEV1 during the hypertonic saline challenge, the response
coxon signed-rank test.
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Figure 1 ROC curves of the isotonic and hypertonic
histamine challenges. The numbers beside the curves
represent various cut-off values for PC20 (mg/ml).
Figure 2 The airway responsiveness to isotonic (a) and
hypertonic (b) histamine challenge in 15 healthy sub-
jects, 16 asthmatic subjects without inhaled corticoster-
oid treatment, and 16 asthmatic subjects with this
treatment. The horizontal line indicates a PC20 value of
1mg/ml, a cut-off value suggested by the ROC curve.
Hypertonicity of the challenge solution may increase the diagnostic accuracy of histamine challenge 731a statistically significant difference in the respon-
siveness to hypertonic histamine between steroid-
naive and steroid-treated asthmatic subjects (Table
3) whereas the responsiveness to isotonic histamine
did not differ significantly between these sub-
groups. The responses to hypertonic saline were
mild. It induced a statistically significant
(P ¼ 0:008) change in FEV1 in steroid-naive asth-
matic subjects only. A 20% or greater fall in FEV1
was only demonstrated by one steroid naive and
one steroid-treated asthmatic subject and the
responses to saline are therefore expressed as the
percentage change in FEV1 after the final saline
inhalation (Table 3). The PC20 of the hypertonic
histamine challenge was highly repeatable, with a
single determination 95% range of 71.35 doubling
concentrations and with an intraclass correlation
coefficient of 0.965.Safety issues
None of the challenges induced any statistically
significant changes in the systolic blood pressure
but all induced slight changes in heart rate.
Hypertonic saline decreased it by 4 (2–6) beats/
min (Po0.0001), isotonic histamine increased it by
3 (1–5) beats/min (P ¼ 0:006), and hypertonic
histamine increased it by 5 (2–8) beats/min
(P ¼ 0:001). The hypertonic histamine-induced
bronchoconstriction was rapidly reversed by
0.2mg of salbutamol in the asthmatic subjects.
Without the bronchodilating treatment, the recov-ery was almost complete within 1 h after the
challenge (Fig 3). The late PEF recordings showed
no signs of late asthmatic responses after any of the
challenges (data not shown).Side effects
There were the following statistically significant
(Po0.001) increases in visual analogy scale symp-
tom readings: Saline challenge induced throat
irritation (17 (11–24)mm). Isotonic histamine in-
duced dyspnea (38 (28–47)mm), throat irritation
(24 (16–32)mm), and skin flushing (8 (3–13mm).
Hypertonic histamine induced dyspnea (39
(29–49)mm), throat irritation (40 (30–51)mm),
and skin flushing (17 (8–26)mm). Though not
included in the visual analogy scale lines, nasal
running and sputum production were reported by
some asthmatic patients during all challenges. The
total number of coughs was higher during the
ARTICLE IN PRESS
Figure 3 The mean change in FEV1 from baseline (B) in
the ten asthmatic subjects who were given 0.2mg of
salbutamol after the first hypertonic histamine challenge
(broken line), and who spontaneously recovered after the
second hypertonic histamine challenge (solid line).
H.O. Koskela et al.732hypertonic histamine challenge than during the
isotonic histamine and the hypertonic saline chal-
lenge (40 (31–50) coughs, 20 (13–28) coughs, and 27
(15–39) coughs, respectively, Po0.0001). In gen-
eral, the subjects experienced the hypertonic
histamine challenge as more unpleasant than the
hypertonic saline and the isotonic histamine chal-
lenge (49 (39–59)mm, 33 (25–42)mm, and 38
(29–48)mm, respectively, P ¼ 0:001). In the symp-
tom diary after the challenges up to the following
morning there were the following infrequent
reports about side effects after hypertonic and
isotonic histamine challenges: headache (five and
two out of the 47 subjects, respectively), hoarse-
ness (eight and four subjects), and cough (four and
five subjects).Discussion
The present study demonstrated that it is possible
to increase the diagnostic accuracy of histamine
challenge by using a hypertonic challenge solution.
The rise in tonicity of the challenge solution
decreased the histamine PC20 values in steroid-
naive asthmatic subjects but was without effect on
those values in healthy and steroid-treated asth-
matic subjects. As a consequence, the difference in
histamine responsiveness between healthy and
steroid-naive asthmatic subjects increased and
the diagnostic accuracy of the histamine challenge
therefore improved. This feature of the hypertonic
histamine challenge may be especially advanta-
geous in a situation where there is a high degree ofdiagnostic uncertainty, like in case of the asthmatic
patients who participated in the present study. The
authors stress that the patients in the present study
were not pre-selected on a basis of responsiveness
to any kind of airway challenge but probably well
represent an asthmatic population referred to a
tertiary hospital due to diagnostic difficulties at the
primary health care level. The present study also
demonstrated that hypertonic histamine challenge
is safe and gives well repeatable results. However,
it induced more side-effects than the conventional,
isotonic histamine challenge.
The decrease in the histamine PC20 values by the
rise in challenge solution tonicity in steroid-naive
asthmatic subjects is probably related to the
increased sensitivity of asthmatic airways to var-
ious osmotic stimuli.23 Indeed, inhalation of hyper-
tonic saline in the present study induced
statistically significant bronchoconstriction only in
the steroid-naive asthmatic subjects. On the basis
of the present knowledge about hypertonic aero-
sols,24 the hypertonic-histamine induced broncho-
constriction in steroid-naive asthmatic subjects
was probably a sum effect of exogenous histamine
plus the various endogenous bronchoconstrictive
mediators released by the airway mast cell. The
airway mast cell is capable to release smooth
muscle-active mediators like prostaglandin D2,
cysteinyl-leukotrienes, as well as histamine, in
response to a rise in ambient tonicity.24,25
Theoretically, there might also be technical
factors, which could have explained the difference
in histamine PC20 values between isotonic and
hypertonic histamine challenges in the steroid-
naive asthmatic subjects. Thought the volume
output of our nebuliser was not affected by the
change in challenge solution tonicity, we do not
know the retained doses of the produced aerosols
in each region of the airways. Particle size is the
prime factor governing the fraction of inhaled
particles that penetrates past the oropharynx and
enters the lungs, and the particle fraction that
deposits in each region of the airways.26 Therefore,
if the change in challenge solution tonicity had
affected the droplet size distribution in the present
study, it could have caused a change in the lower
airway histamine dose. For example, hypertonic
droplets gain water and grow within the airways
during inhalation whereas isotonic droplets main-
tain their size.26 This rise in droplet size probably
increases the airway deposition of the initially very
small droplets, but may also decrease the lower
airway deposition of the initially 2–8 mm droplets,
since fewer than half particles larger than 8 mm get
past the larynx during tidal breathing.26 To exactly
measure the droplet size distribution in the present
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humidity of 99% should have been used.26 Such a
device was not available for the authors and the
droplet size distribution was therefore not mea-
sured. However, since the change in histamine
challenge solution tonicity did not affect the
histamine PC20 values in the healthy and steroid-
treated asthmatic subjects, the authors assume
that technical factors associated with the change in
the challenge solution tonicity had not changed the
retained dose of histamine in the lower airways
significantly, and can therefore not explain the
finding in steroid-naive asthmatic subjects.
Direct airway challenges such as the histamine
challenge have often been accused of being
insensitive in demonstrating the effect of inhaled
corticosteroid treatment in asthma. According to a
meta-analysis, a long-term treatment with high
doses of inhaled corticosteroids causes on average
of just 1.16 doubling doses or concentrations
change in the airway responsiveness to direct
stimuli.27 Our results, though obtained from a
cross-sectional study, are in line with this observa-
tion. Indeed, there was just a 0.9 doubling
concentration difference in the isotonic histamine
PC20 between steroid-naive and steroid-treated
asthmatic subjects, which was not statistically
significant in our rather small study group. On the
contrary, the difference in the hypertonic hista-
mine PC20 between the steroid-naive and steroid-
treated asthmatic subjects was 2.2 doubling con-
centrations and this was statistically significant.
Therefore, hypertonic histamine challenge may be
more sensitive than isotonic histamine challenge in
demonstrating the effect of inhaled corticosteroid
treatment in asthma. This is probably based on the
fact that airway responsiveness to hypertonic
aerosols is very sensitive to the effects of inhaled
steroids.10–13 However, a follow-up study would be
needed to confirm the findings of the present study.
Comparison of our results with those of previous
studies is difficult due to technical and methodo-
logical differences. The present histamine chal-
lenge method is developed from that described by
Cockcroft et al.,28 who used a jet nebuliser with a
volume output of 0.13ml/min. However, we had to
use an ultrasonic nebuliser, which is recommended
for non-isotonic challenges because it produces
more dense aerosols.21 We intended to use a
relatively low-volume output ultrasonic nebuliser
but its output (0.44–0.48) was still considerably
higher than that used by Cockcroft et al. Since
nebuliser volume output is a crucial factor deter-
mining the airway response,29,30 direct comparison
of our results with those obtained using the
Cockcroft method is not valid. Similarly, compar-ison of our hypertonic saline responses with those
in previous studies is difficult since in previous
studies the output of the ultrasonic nebulisers has
been at least 1.2ml/min,21 more than twice to that
of the Omrons nebuliser. This and the decision to
challenge the asthmatic patients outside the pollen
season probably mainly explain why so few asth-
matic patients responded to hypertonic saline in
the present study.
Hypertonic histamine challenge induced more
side effects than the other two challenges, mainly
cough and throat irritation. However, it produced
well repeatable responses and was safe. It did not
induce any clinically significant changes in heart
rate or blood pressure. There were no significant
adverse effects up to the following morning and the
late PEF recordings showed no evidence of any late
asthmatic reaction. The induced bronchoconstric-
tion was rapidly reversible with a conventional dose
of inhaled salbutamol, and without treatment it
almost completely vanished within 1 h. Due to the
fact that the steroid-naive asthmatic patients
usually responded to less than 1mg/ml hypertonic
histamine concentration, in future this test could
probably be terminated after the administration of
2 or 4mg/ml solution. This practice would decrease
the side effects and therefore increase the accept-
ability of the hypertonic histamine challenge.
In conclusion, it seems that the diagnostic
accuracy of histamine challenge can be improved
by using a hypertonic challenge solution. Hyper-
tonic histamine challenge may also be more
capable to detect the effects of inhaled corticos-
teroid treatment than the conventional, isotonic
histamine challenge. Further studies with a larger
number of patients are needed to confirm these
findings and also, to explore whether these benefits
of hypertonic histamine challenge outweigh the
slightly greater side effects associated with this
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